Clinical Trial Update: Randomized, Double Blind, Placebo-controlled Topical Resiquimod Adjuvant for NY-ESO-1 Protein Vaccination [Phase 1]

View source ↗

Summary

A Phase 1 randomized, double‑blind, placebo‑controlled trial evaluated topical resiquimod as an adjuvant to NY-ESO-1 protein vaccination and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Resiquimod (resiquimod)

Snippet

Sponsor: Nina Bhardwaj | Conditions: Tumors | Phase 1 | Status: COMPLETED